Receive our newsletter – data, insights and analysis delivered to you
  1. Market Data
October 13, 2017

Deals this week: GlycoMimetics, Erytech Pharma, ObsEva

US-based clinical-stage biotechnology company GlycoMimetics Inc plans to raise $100m by issuing shares of its common stock from time to time in a public offering.

US-based clinical-stage biotechnology company GlycoMimetics Inc plans to raise $100m by issuing shares of its common stock from time to time in a public offering.

The company plans to use funds for the production and clinical trials of its drug candidates and for general corporate purposes.

French biopharmaceutical company Erytech Pharma SA plans to raise $100m through an initial public offering of American Depositary Shares.

The company plans to use the funds for conducting Phase III clinical trials on eryaspase in the US and Europe, and other general corporate purposes.

ObsEva SA has issued seven million shares of its common stock and prepaid warrants priced at $8 a share in a private placement to raise $60m.

“The company intends to use funds from the offering to carry out Phase trials of ALLN-177 and other general corporate purposes.”

The French biopharmaceutical company plans to use the funds towards the research and development of its drug candidates.

Content from our partners
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide
Why Asia-Pacific is the next frontier for decentralized clinical trials

US-based biopharmaceutical company Allena Pharmaceuticals Inc plans to issue shares of its common stock in an initial public offering (IPO) to raise $92m.

The company intends to use funds from the offering to carry out Phase trials of ALLN-177 and other general corporate purposes.

Spero Therapeutics Inc plans to raise $86.25m in an initial public offering (IPO) of shares of its common stock.

The US-based biopharmaceutical company plans to use the funds for the clinical trials of SPR994 and SPR994 and for working capital purposes.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU